1. Market Research
  2. > Pharmaceutical Market Trends
The Role of Medical Affairs in a Successful Commercial Launch

The Role of Medical Affairs in a Successful Commercial Launch

  • November 2015
  • ID: 3607555
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Drive greater product launch success by fully engaging the medical affairs department. Ensure maximum exposure and positive uptake of new therapies by harnessing their talents in scientific interpretation, evidence gathering, trial planning and KOL/payer engagement.

The Role of Medical Affairs in a Successful Commercial Launch is a research-based expert views report for industry management who must plan and execute product launch strategies. The report is packed with actionable insights on how and where medical affairs can play a critical role in pre and post launch. Learn from the experience of 8 medical affairs professionals working for major pharma/biotech companies in the US and Europe.

Answering Key Questions:


Early engagement: KOLs play a critical role in the clinical development of a product. At what development stage should medical affairs get involved as the potential new product progresses to launch?
Late-stage study design: Phase III studies are critical for gaining regulatory approval – how can medical affairs help refine trial design?
Involvement with launch planning: In what ways can medical affairs support their commercial colleagues and when should they get involved with launch planning?
Evidence gathering: How do medical affairs studies contribute to a successful launch and how can “real world” studies help refine the value proposition?
Effective communications: In which areas can medical affairs be influential when developing communication strategies that meets the needs of multiple stakeholders?
Getting the message across: How can medical affairs play a critical role in training MSLs and commercial staff to ensure consistent and evidence-based product messaging?
Post launch involvement: The broadening role of medical affairs after launch is becoming critical. Where, how and why?
Market Access: What are the arguments for medical affairs taking a wider role in market access?


With This Report You Will Be Able To:


Know why it is critical to involve medical affairs throughout the clinical development phase of a drug.
Harness your medical team’s expertise for optimum product positioning.
Build a powerful evidence-based case for your product through well thought out studies and research.
Benefit from real world knowledge gained by MSL engagement with clinical experts and stakeholders.
Use medical affairs to establish clear evidence-based communications and consistent product messaging.
Appreciate to what extent medical affairs activity now goes well beyond data dissemination and governance.
Understand key internal challenges medical affairs departments face.


Key Topics Explored

How medical affairs can play a greater role in market access and payer engagement.
Medical affairs teams are trusted in the health community and knowing how to leverage their high-level stakeholder contacts can bring real commercial advantage.
Medical affairs see the bigger picture and can often identify opportunities and issues that highly focussed R&D/commercial teams miss.
Medical affairs is the bridge between R&D and commercial, and bring benefits and insights to both.
Medical affairs teams often struggle to secure sufficient funding and value recognition for their ever widening workload – is this a lesson for senior management?
Bottom line: With deeper market knowledge than R&D and commercial teams, medical affairs can add real value from product concept to Phase III trials and beyond.


Expert Contributors To The Report:

Global Medical Affairs Director – Top 10 Pharma Company
Vice-President of Medical Affairs, US – Medium-sized Pharma Company
Medical Director – Top 10 Pharma Company
Former Vice President, Head of Medical Affairs Europe and Canada – Top 10 Pharma Company
Global Medical Affairs Lead – Top 10 Pharma Company
Franchise Head, Medical Communications – Top 10 Pharma Company
Executive Medical Director, Medical Affairs – Top 10 Pharma Company
Global Head of R&D and Medical Affairs – Biotech Company

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Diabetic Foot Ulcers - Pipeline Review, H2 2019

Diabetic Foot Ulcers - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Diabetic Foot Ulcers - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H2 2019, provides an overview of the Diabetic ...

2020 Italy Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies

2020 Italy Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies

  • $ 3500
  • January 2020

The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget.This new study contains 402 pages, and is designed to help current suppliers ...

2020 UK Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies

2020 UK Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing: Supplier Shares by Country and Segment Forecasts, Emerging Technologies, Competitive Strategies

  • $ 3500
  • January 2020

The report is available by section, market segment, and can be custom-tailored to your specific information needs and budget.This new study  contains 408 pages, and is designed to help current suppliers ...

Global Bioburden Testing Industry $ 5450 February 2020

Global NGS-based RNA-seq Industry $ 5450 February 2020


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on